Biocon Analyst Review May 2026
- May 16, 2026
- Posted by: Neeraj Pandey
- Category: News
This Biocon analyst review for May 2026 covers the key data investors need for BIOCON at its current price of Rs 370. Biocon (NSE: BIOCON) is India’s leading biopharmaceuticals company with a market capitalisation of approximately Rs 44,000 crore, specialising in biosimilars, small molecule APIs, and generic formulations through Biocon Biologics and Syngene International. The analyst consensus target of Rs 430 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether BIOCON achieves that target through FY27.
Click Here – Get Free Investment Predictions
Biocon Company Snapshot May 2026
Biocon Biologics has launched biosimilars including Ogivri (trastuzumab), Semglee (glargine insulin), Hulio (adalimumab), and Yuflyma in the US and Europe. The Viatris partnership and own-label launches in the US are key commercial milestones. The table below summarises the key data referenced in this Biocon analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | BIOCON |
| Sector | Pharmaceuticals – Biosimilars |
| CMP (May 2026) | Rs 370 |
| 52 Week High | Rs 395 |
| 52 Week Low | Rs 240 |
| Market Cap | Rs 44,000 Crore |
| Trailing P/E | 40.00x |
| Analyst Consensus Target | Rs 430 |
| Bull Case Target | Rs 520 |
| Bear Case Target | Rs 260 |
Analyst Insight in This Biocon Analyst Review
Associate Director Kunal Singla suggests watching Biocon closely in May 2026. At the current market price of Rs 370, Kunal Singla flags Pharmaceuticals – Biosimilars sector dynamics as a key driver for BIOCON’s near-term price action. He notes support in the Rs 245 to Rs 352 zone and flags any sustained close above Rs 392 as a positive signal worth tracking. Kunal Singla’s perspective on Biocon adds a layer of professional technical analysis to this Biocon analyst review and is not a buy recommendation.
Technical Analysis in This Biocon Analyst Review
At Rs 370, BIOCON is trading within its 52-week band of Rs 240 to Rs 395. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 245 to Rs 352 band while resistance is seen in the Rs 392 to Rs 400 zone. A sustained move above Rs 392 could open the path toward the analyst consensus of Rs 430.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 245 to Rs 352 – investors tracking this Biocon analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
- Resistance Zone: Rs 392 to Rs 400 – a sustained close above Rs 392 would be a positive breakout signal worth flagging.
- Medium-Term Target: The analyst consensus of Rs 430 represents the base-case upside for this Biocon analyst review.
Business Segment Analysis
Biocon Biologics (Biosimilar Commercial Assets – Global)
This is the primary revenue and margin driver for Biocon, directly supporting the earnings trajectory toward the consensus target of Rs 430.
Syngene International (CRAMS – Research Services)
This segment adds scale and diversification to Biocon’s business model and is a meaningful EPS contributor through FY27 and FY28.
Small Molecule APIs and Generic Formulations
This represents the medium-term growth frontier for Biocon and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Biocon Analyst Review
At Rs 370, Biocon trades at a trailing P/E of 40.00x. This Biocon analyst review presents three scenarios: a bull case of Rs 520 on strong earnings delivery, a base case of Rs 430 at consensus, and a bear case of Rs 260 if macro headwinds persist. Q1 FY27 results will be the first key validation point.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 520 | Strong earnings and sector tailwinds |
| Base Case (Consensus) | Rs 430 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 260 | Earnings miss or macro headwinds |
Trade Outlook for Biocon
Based on the technical and fundamental analysis in this Biocon analyst review, investors might watch BIOCON near the support zone of Rs 245 to Rs 352 for potential opportunities. A flag above Rs 392 could suggest improving momentum toward Rs 430. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Biocon in FY27
A well-rounded Biocon analyst review must assess downside risks. Key risks for Biocon include a macro slowdown affecting Pharmaceuticals – Biosimilars sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in BIOCON.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Biocon Analyst Review Verdict for 2026
This Biocon analyst review concludes that at Rs 370, BIOCON offers a defined risk-reward with a consensus target of Rs 430. The 52-week range of Rs 240 to Rs 395 provides context on the current entry point. Use this Biocon analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on BIOCON.
Frequently Asked Questions: Biocon Analyst Review 2026
What is the analyst target for Biocon in 2026?
The analyst consensus target is Rs 430, with a bull case of Rs 520 and a bear case of Rs 260. Monitor Q1 FY27 earnings for confirmation.
Is Biocon a good investment at Rs 370?
At Rs 370 with a P/E of 40.00x and a consensus target of Rs 430, this Biocon analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Biosimilars sector. Always consult a SEBI-registered advisor before investing.
What is Biocon’s 52-week high and low?
The 52-week high is Rs 395 and the 52-week low is Rs 240. At Rs 370, BIOCON is positioned within this range as noted in this Biocon analyst review.
What are the key risks for Biocon?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Biosimilars sector.
Where can I get live data and analyst targets for Biocon?
Track Biocon’s live price and analyst targets on the Univest Screener alongside professional financial advice.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
